We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Exemestane (Aromasin) — steroidal, irreversible aromatase inhibitor
A steroidal, irreversible ('suicide') aromatase inhibitor (Aromasin) approved for hormone-receptor-positive breast cancer, where its evidence is strong (the IES switch trial, MAP.3 prevention, and head-to-head with anastrozole in MA.27). It is the steroidal counterpart to anastrozole and letrozole, and because its metabolite is mildly androgenic it is sometimes claimed to spare bone — but the trials show it still lowers bone-mineral density and raises fracture risk. Used off-label in men to lower estradiol and raise testosterone, a small crossover RCT confirms it does shift the hormones, but estrogen is required for the male skeleton and lipids. A prescription drug, not a supplement, and NOT a longevity drug.
Prescription medication — not a dietary supplement
Exemestane is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Exemestane studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 1997–2026 with a typical study size of 20 participants.
Based on 140 studies · 14 meta-analyses · 117 RCTs · 1,290 total participants
Confidence
High confidenceBy outcome
Exemestane has strong, multi-trial evidence in its approved indications — the IES switch trial, the TEAM monotherapy trial, head-to-head equivalence with anastrozole in MA.27, and a 65% reduction in invasive breast cancer in the MAP.3 prevention trial — and a small crossover RCT confirms it lowers estradiol and raises testosterone in men. But the off-label male use is unproven for any functional outcome, its 'bone-sparing' reputation does not hold (a TEAM bone meta-analysis showed it decreased spine BMD ~3.5% at 2 years and the EBCTCG meta-analysis found more fractures than tamoxifen), and estrogen is required for the male skeleton and lipids — so the off-label men's-health case stays emerging.
138 rigorous studies
118 randomized trials · 14 meta-analyses · 6 systematic reviews
Our evidence rating for Exemestane is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
115 trials ongoing or recruiting · 180 completed on ClinicalTrials.gov
81 of the completed trials have posted results
Registered trials show research momentum for Exemestane, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Aug 2026
Exemestane (Aromasin) is a steroidal, irreversible aromatase inhibitor — a 'suicide' inhibitor that binds the aromatase (CYP19A1) enzyme covalently and permanently inactivates it, unlike the reversible non-steroidal inhibitors anastrozole and letrozole.
Aromatase converts androgens (testosterone, androstenedione) into estrogens (estradiol, estrone), so blocking it lowers circulating estrogen.
Its approved, evidence-rich use is in postmenopausal hormone-receptor-positive breast cancer: the landmark Intergroup Exemestane Study (IES) showed that switching to exemestane after two to three years of tamoxifen significantly improved disease-free survival versus completing five years of tamoxifen; the MA.27 phase III trial found exemestane neither superior nor inferior to anastrozole as up-front adjuvant therapy; the TEAM trial established exemestane monotherapy as an appropriate option; and the MAP.3 trial (Goss, NEJM 2011) showed exemestane reduced the incidence of invasive breast cancer by 65% in postmenopausal women at elevated risk — a genuine chemoprevention result.
Everything else is off-label.
Because exemestane is a steroid and its principal metabolite (17-hydroxyexemestane) is mildly androgenic, it has been marketed as the 'bone-sparing' aromatase inhibitor — but that claim does not hold up: a meta-analysis of the TEAM bone sub-studies showed exemestane DECREASED lumbar-spine bone-mineral density by ~3.5% at two years while tamoxifen INCREASED it, and the EBCTCG patient-level meta-analysis recorded significantly more fractures on aromatase inhibitors than tamoxifen.
In men, the same mechanism shifts the testosterone/estradiol balance: a small randomized crossover study in healthy young men showed exemestane suppressed estradiol by ~38% with a reciprocal ~60% rise in testosterone, which is why it is reached for off-label in TRT-adjacent and bodybuilding contexts.
The crucial honesty gate: estrogen is not just a 'female' hormone — in men estradiol is the dominant regulator of bone-mineral density and contributes to lipid and cardiovascular health, so chronically suppressing it risks bone loss and adverse lipids exactly as it does in women.
There are no large trials demonstrating a functional benefit (strength, body composition, hard outcomes) from exemestane in men. Exemestane is a prescription drug; it is approved only for breast cancer, used off-label in men, and is NOT a longevity or healthspan drug.
The score reflects strong evidence in the approved oncology indications (treatment and prevention) and a reliable hormonal effect in men, set against unproven functional benefit off-label and a real, documented bone-density/fracture cost from estrogen suppression.
As a steroidal 'suicide' inhibitor, exemestane binds the aromatase enzyme covalently and permanently inactivates it — lowering estradiol until new enzyme is synthesized, unlike the reversible non-steroidal AIs.
Lower estradiol reduces negative feedback at the hypothalamus and pituitary, raising LH and endogenous testosterone production in men — a reciprocal testosterone rise accompanies the estradiol drop.
Exemestane's principal metabolite (17-hydroxyexemestane) is weakly androgenic, which is why it was proposed to spare bone relative to non-steroidal AIs — but trials show it still lowers BMD.
Estradiol is the dominant regulator of bone-mineral density and contributes to lipids in both sexes; suppressing it lowers BMD and raises fracture risk — the central trade-off of the drug.
How Exemestane works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Off-label and unproven for strength/body-composition or any functional benefit; monitor estradiol and bone — over-suppression harms the male skeleton and lipids.
Higher fracture risk — estrogen suppression worsens bone despite the steroidal metabolite; weigh carefully and monitor DXA.
Aromatase inhibitors are ineffective in premenopausal women unless combined with ovarian suppression, and are teratogenic — not appropriate outside specialist oncology protocols.
Estrogens directly counteract exemestane's mechanism and would negate its estrogen-lowering effect.
Exemestane is metabolized by CYP3A4; strong inducers lower its exposure and a higher dose may be needed when co-administered.
Often co-prescribed to offset aromatase-inhibitor-driven bone loss — a clinically relevant interaction to plan around, not avoid.
Tip: Estrogen suppression lowers BMD despite the mildly androgenic metabolite; monitor DXA, ensure calcium/vitamin D, consider bone agents. Avoid over-suppressing estradiol.
Tip: A well-known aromatase-inhibitor effect (musculoskeletal symptoms were the most common in TEAM); usually manageable, occasionally limits adherence.
Tip: A direct consequence of low estrogen; usually tolerable and reversible on stopping.
Tip: Crashing estradiol in men harms libido and mood; keep E2 in a healthy range rather than as low as possible.
Exemestane has an evidence score of 4.9/10 — emerging evidence based on 133 indexed studies, including 2 meta-analyses. A steroidal, irreversible ('suicide') aromatase inhibitor (Aromasin) approved for hormone-receptor-positive breast cancer, where its evidence is strong (the IES switch trial, MAP.3 prevention, and head-to-head with anastrozole in MA.27). It is the steroidal counterpart to anastrozole and letrozole, and because its metabolite is mildly androgenic it is sometimes claimed to spare bone — but the trials show it still lowers bone-mineral density and raises fracture risk. Used off-label in men to lower estradiol and raise testosterone, a small crossover RCT confirms it does shift the hormones, but estrogen is required for the male skeleton and lipids. A prescription drug, not a supplement, and NOT a longevity drug. Representative study: PMID 35123662.
The commonly studied dose of Exemestane is Approved breast-cancer dose is 25 mg once daily with food. Off-label use in men typically uses lower or intermittent dosing (e.g. 12.5-25 mg every other day to a few times weekly) under a clinician, titrated to estradiol and testosterone with bone monitoring. A prescription drug; not an approved men's-health regimen.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Exemestane is with meals. Take it with food. Bioavailability is increased ~40% when taken after a meal, so the approved 25 mg dose is taken with food.
Exemestane should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are bone-density loss / increased fracture risk, joint / muscle aches (arthralgia), hot flushes / fatigue. Use caution if any of these apply to you: Premenopausal women / pregnancy (teratogenic; approved only postmenopausal); Pre-existing osteoporosis or high fracture risk (estrogen suppression worsens bone); Hypersensitivity to exemestane.
Soy Isoflavones
Likely helpsPlant compounds with weak estrogenic effects that support menopausal symptoms, bone health, and cardiovascular function.
DHEA
Probably helpsAdrenal hormone precursor that declines with age, supporting hormone balance, energy, and body composition.
Melatonin
Probably helpsRegulates the circadian clock to reduce sleep onset time — most effective at low doses (0.3-1mg) for jet lag and rhythm disorders.
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Explore: Best supplements for Women's HealthBest supplements for Men's Health
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 140 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research